Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) shares are trading higher Wednesday after the company announced the publication of pre-clinical data on its lead clinical compound, LB-100. The Details: The company announced the publication of pre-clinical data in the online journal, “Cancer Discovery”, showing that its lead clinical compound, LB-100, can force cancer cells to give up their cancer-causing properties in a paper entitled “Paradoxical activation of oncogenic signaling as a cancer treatment strategy.” Lixte said the finding opens a potentially new treatment strategy in addition to …